Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in NSCLC
Portfolio Pulse from
Akeso, Inc. has enrolled the first patient in a Phase 3 trial for its bispecific antibody, cadonilimab, aimed at treating NSCLC post-chemoradiotherapy.
February 13, 2025 | 1:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akeso, Inc. has initiated a Phase 3 trial for cadonilimab, a PD-1/CTLA-4 bispecific antibody, marking a significant step in its development for NSCLC treatment.
The initiation of a Phase 3 trial is a critical milestone in drug development, indicating progress towards potential market approval. This could positively impact Akeso's stock as it reflects advancement in their product pipeline.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80